In summary, our study report for the first time that DDX17 acts as a negative regulator of Klf4 transcriptional activity in HCC and is an independent prognostic factor of HCC, which might be a potential therapeutic target. This evidence concerns the gene KLF4 and hepatocellular carcinoma.